ALK and non-small cell lung carcinoma: In the era of personalized medicine, acquisition of sufficient quality and quantity of tumor tissue for histologic diagnosis and molecular testing (epidermal growth factor receptor mutations and anaplastic lymphoma kinase fusions) is becoming increasingly important for the treatment of patients with non-small cell lung cancer [25,26].